Kumamoto

(to all of the medical institutions) about application such as medical institutions in hepatitis treatment medical expenses subsidy program

The last update date:

Addition for the furtherance of medical expenses

 Following the fact that dakuratasubiru hydrochloride, asunapurebiru bekurabubiru hydrochloride combination lock (interferon-free treatment) and tenohobiruarafenamidofumaru acid salt (nucleic acid analog preparation treatment for patients with hepatitis B) became insurance adaptation on February 15, 2017, in Kumamoto, we aim at this treatment for the hepatitis medical expenses furtherance.

 Object: Chronic hepatitis C or C type compensation-related cirrhosis (cello group 1 (jienotaipu 1)) of Child-Pugh classification A

    Type B chronicity liver disease

 

  Following the fact that Elba building and gurazopurebiru hydrate (interferon-free treatment) became insurance adaptation on November 18, 2016, in Kumamoto, we aim at this treatment for the hepatitis medical expenses furtherance.

 Object: Chronic hepatitis C or C type compensation-related cirrhosis (cello group 1 (jienotaipu 1)) of Child-Pugh classification A

 

 Following the fact that omubitasubiru hydrate, paritapurebiru hydrate, ritonavir combination agent (interferon-free treatment) became insurance application on November 26, 2015, in Kumamoto, we aim at this treatment for the hepatitis medical expenses furtherance. In addition, we aim at this treatment for the hepatitis medical expenses furtherance in Kumamoto as production and sales approval matter partial change of omubitasubiru hydrate, paritapurebiru hydrate, ritonavir combination agent and ribavirin became approval, insurance application on September 28, 2016. 

  Object: Chronic hepatitis C of cello group 1 (jienotaipu 1) or C type compensation-related cirrhosis of Child-Pugh classification A

     Chronic hepatitis C of cello group 2 (jienotaipu 2)

 

   Following the fact that treatment with cash register pass Building/sohosububiru combination lock (interferon-free treatment) became insurance application on August 31, 2015, in Kumamoto, we aim at this treatment for the hepatitis medical expenses furtherance.

  Object: Chronic hepatitis C or C type compensation-related cirrhosis (cello group 1 (jienotaipu 1)) of Child-Pugh classification A 

 

  Rebbe Dole capsule (generic name: ribavirin) for chronic hepatitis C of cello group 2 (jienotaipu 2) by combination with sohosububiru or C type compensation-related cirrhosis will be included in medical expenses furtherance object on July 29, 2015. → [notice] about the handling of rebbe Dole capsule in hepatitis treatment special promotion business 

 

  Following the fact that sohosububiru and ribavirin combination therapy (interferon-free treatment) became insurance application on May 20, 2015, in Kumamoto, we aim at this treatment for the hepatitis medical expenses furtherance.

  Object: Chronic hepatitis C or C type compensation-related cirrhosis (cello group 2 (jienotaipu 2)) of Child-Pugh classification A

 

 

About interferon-free treatment after interferon-free treatment unsuccessfullness

 About interferon-free treatment, it is the furtherance only for one time of principle.

 

  But, about person with interferon-free history of treatment, liver disease medical treatment cooperation base Hospital can aim for the furtherance some other time only when it is judged that it is appropriate to perform re-treatment using other interferon-free therapeutic drug by the Japan Society of Hepatology liver specialist holding a full-time position.

(when sohosububiru for patient of cello group type 2 (jienotaipu 2) and ribavirin combination therapy (interferon-free treatment) is unsuccessful note, as for the re-treatment, there are none now.)

 

 Thing which had start of therapy after December 1, 2015 becomes a target of the furtherance. Person applying for re-treatment to March 31, 2016 can sail up the start date of the medical expenses furtherance based on proposal until December 1, 2015.

 

 When doctor that medical certificate is made is not the Japan Society of Hepatology liver specialist holding a full-time position in liver disease medical treatment cooperation base Hospital, "laboratory findings" submit "statement of position of the Japan Society of Hepatology liver specialist holding a full-time position in liver disease medical treatment cooperation base Hospital" and "medical certificate" to the Japan Society of Hepatology liver specialist holding a full-time position in liver disease medical treatment cooperation base Hospital of this prefecture, and it is necessary to inquire.

 

 We can download "medical certificate" in re-treatment and "written opinion of the Japan Society of Hepatology liver specialist holding a full-time position in liver disease medical treatment cooperation base Hospital" from the following. In re-treatment, to "liver disease center", please about submissions such as necessary laboratory findings, inquiry.

 

PDF Medical certificate [re-treatment] for interferon-free treatment With new window(PDF: 164.1 kilobytes)

Excel Statement of position (statement of position for interferon-free treatment (re-treatment)) of the Japan Society of Hepatology liver specialist holding a full-time position in Kumamoto liver disease medical treatment cooperation base Hospital With new window(Excel: 18.2 kilobytes)

 

 Liver disease center contact information
 TEL: 096-372-1371
 
 〒860-8556
 Chuo-ku, Kumamoto-shi Honjo 1-1-1
 Foreign medical treatment ridge the fourth floor in the national university corporation Kumamoto University medical department hospital
 Liver disease center

 

To all of the insurance medical institutions applied for such as designated medical institutions

 There is address type B in the prefecture to be able to receive interferon therapy, interferon-free treatment and nucleic acid analog preparation treatment by type C virus-related hepatitis, and to receive the public money furtherance of medical expenses, and when it needs interferon therapy, interferon-free treatment, nucleic acid analog preparation treatment, it is diagnosed, and it is necessary for specialty medical institution (designated medical institution) which the prefecture appointed to receive authorization of the prefecture.

 In addition, what can receive the furtherance applies beforehand, and a certain insurance medical institution (designated medical institution and treatment conduct medical institution) and health insurance pharmacy described in identification of recipient is limited when we had a medical examination.

There are two ways of following medical institutions to medical institution pertaining to subsidy program of hepatitis treatment costs. (it is necessary for all to make a contract with the prefecture)

Division  
Designated medical institution Medical institution which gives making of medical certificate pertaining to identification of recipient grant application, introduction treatment.
Treatment conduct medical institution

Medical institution which succeeds treatment based on treatment plan of designated medical institution, and is treated.

※We cannot make medical certificate pertaining to identification of recipient grant application.

We can confirm medical institution pertaining to interferon therapy and interferon-free treatment in this page.

We can confirm medical institution pertaining to nucleic acid analog preparation treatment in this page.

 

◆Designated medical institution-designated requirements

1. Interferon therapy and interferon free treatment-designated medical institution              (conduct of medical certificate making, introduction treatment)

 As a general rule, among insurance medical institutions meeting either requirement of following (1) - (3), the prefecture does with medical institution which admitted by application. In authorization, we examine based on the treatment results of medical certificate making doctor.

(1) Authorized facility of the Japan Society of Hepatology or related facility

(2) Facility where it is authorized facility of the Japanese Society of Gastroenterology or related facility and specialist in Japan Society of Hepatology holds a full-time position

(3) Medical institution except the above

 ※But, about medical institution of (3), it is limited when hepatitis measures meeting admitted that it is equal to (1) mentioned above and (2).

 In addition, designated medical institution has you report curative effect after completion of treatment of interferon therapy recipient and interferon-free treatment recipient in (after completion of treatment six months later). (curative effect judgment report style)

PDF ○Q&A (product for medical institutions) about the handling of hepatitis treatment special promotion business ※As of H26.1 month [PDF file/187KB]

H27.6.1 Flow of the medical expenses furtherance


 2. Nucleic acid analog preparation treatment-designated medical institution (conduct of medical certificate making, introduction treatment)

 As a general rule, among insurance medical institutions meeting following (1), either requirement of (2), we do with medical institution that the prefecture admitted by application. In authorization, we examine based on the treatment results of medical certificate making doctor.

(1) Base Hospital in Kumamoto liver disease medical treatment cooperation network and specialized medical institution

(2) In addition, medical institution which admitted that Kumamoto hepatitis measures meeting had function that was equal to medical institution of (1)

 PDF (reference) The medical institution registration point With new window(PDF: 70.3 kilobytes) specialized in Kumamoto liver disease (as of H27.4.7)


3. Treatment conduct medical institution (interferon interferon-free, nucleic acid analog preparation treatment is common)

 As a general rule, medical institution that we assumed insurance medical institution which met the following conditions, and the prefecture admitted by application.

 (1) Medical institution which can provide treatment after introduction treatment of recipient in cooperation with designated medical institution.

 (2) Medical institution designated in treatment and medical institution which always measures information sharing, and can obey the instructions.

 (3) Medical institution which is good at report to designated medical institution about treatment result of recipient.

 

Styles such as medical institution applications

  We can download styles such as applications such as designated medical institutions than the following.

  Style

  File downloading
1. Designated medical institution duties application (both sides) PDF Attached sheet style 4 With new window(PDF: 149.8 kilobytes) ※H27.12 partial revision 

PDF ※Mention example [PDF file/361KB] 

2. Treatment conduct medical institution duties application PDF Attached sheet style 6-2 [PDF file/76KB] ※H26.10 partial revision 
PDF ※Mention example [PDF file/200KB] 
3. Self-pay limit monthly basis control documentation 
※Control documentation is united with identification of recipient.
PDF ※Mention example [PDF file/32KB] 
4. Notifications of change such as designated medical institutions PDF Attached sheet style 4-2 [PDF file/41KB] 
PDF ※Mention example [PDF file/56KB] 
5. Reports of refusal such as designated medical institutions PDF Attached sheet style 4-3 [PDF file/23KB] 
PDF ※Mention example [PDF file/46KB] 

6. Receipt certificate
※When we get rid of repayment, and recipient requests

Certificate to make in medical institution or the drugstore

PDF Receipt certificate [PDF file/154KB] ※H26.10 partial revision  
PDF ※Mention example (the surface) [PDF file/82KB] 
7. Curative effect judgment report (both sides) PDF Interferon therapy effect measurement report [PDF file/18KB] 
※We submit only interferon and interferon free treatment-designated medical institution (completion of treatment six months later) PDF ※Mention example [PDF file/1.23MB] 

 

Medical certificate style pertaining to identification of recipient grant application

We relate to this page
Inquiry

Department of Health and Social Services Public Health Emergencies Management Division infectious disease, new influenza measures group
Telephone: 096-333-2240
Fax: 096-387-0167
Email [email protected]
(ID: 5735)

We open with the other window Link having this mark opens with the other window

※When PDF file is attached as materials, Adobe Acrobat(R) is necessary.
When you look at PDF documents, Adobe Reader is necessary. When you are not displayed definitely, please use the latest version.
Kumamoto prefectural government office   〒 862-8570  6-18-1, Suizenji, Chuo-ku, Kumamoto-shi, Kumamoto Tel: 096-383-1111 (main)
Copyright(C) 2015 Kumamoto Prefectural Government. All rights reserved.